ML17032 trial: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 12, 2009, Pages 1745-1751

  Ryu, Min Hee ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Advanced gastric cancer; Capecitabine; Cisplatin; Phase III

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; LAPATINIB; MITOMYCIN C; OXALIPLATIN; PLATINUM DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ANEMIA; BONE MARROW SUPPRESSION; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 73349085566     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.149     Document Type: Review

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
3. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. 31(4), 450-464 (2004).
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72(1), 37-41 (1993).
5. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8(2), 163-168 (1997).
6. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 71(3), 587-591 (1995).
7. Ohtsu A, Shimada Y, Yoshida S et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur. J. Cancer 30A(14), 2091-2093 (1994).
8. Lacave AJ, Baron FJ, Anton LM et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a Phase II trial. Ann. Oncol. 2(10), 751-754 (1991).
9. Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A Phase II trial with prognostic factor analysis. Eur. J. Cancer 30A(9), 1263-1269 (1994).
10. Kim NK, Park YS, Heo DS et al. A Phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71(12), 3813-3818 (1993).
11. Ohtsu A, Shimada Y, Shirao K et al. Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J. Clin. Oncol. 21(1), 54-59 (2003).
12. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 18(14), 2648-2657 (2000).
13. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
14. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009). Description of the Phase III study demonstrating noninferiority of capecitabine-cisplatin versus 5-fluorouracil (5-FU)-cisplatin in patients with advanced gastric cancer (AGC).
15. Hendlisz A, Bleiberg H. Diagnosis and treatment of gastric cancer. Drugs 49(5), 711-720 (1995).
16. Schipper DL, Wagener DJ. Chemotherapy of gastric cancer. Anticancer Drugs 7(2), 137-149 (1996).
17. Hansen RM. 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest. 9(6), 637-642 (1991).
18. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 24(18), 2903-2909 (2006).
19. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24(31), 4991-4997 (2006).
20. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Combination chemotherapies in advanced gastric cancer: an updated systemic review and meta-analysis. Proc. Am. Soc. Clin. Oncol. 25, 18S (2007) (Abstract 4555).
21. Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J. Clin. Oncol. 24(34), 5473-5474; author reply 5474-5476 (2006).
22. Al-Batran SE, Jager E, Scholz M. Chemotherapy for advanced gastric cancer. J. Clin. Oncol. 25(6), 729; author reply 730 (2007).
23. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest. New Drugs 18(4), 343-354 (2000).
24. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 58(4), 685-690 (1998).
25. Verweij J. Rational design of new tumoractivated cytotoxic agents. Oncology 57(Suppl. 1), 9-15 (1999).
26. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T. A pilot Phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64(3), 232-236 (2003). Early study of capecitabine in patients with AGC.
27. Sakamoto J, Chin K, Kondo K et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17(2), 231-236 (2006). This study used an alternative dosing schedule for capecitabine in patients with AGC.
28. Leon-Rodriguez E, Green D, Candelaria M. Oral capecitabine in the treatment of patients with advanced or metastatic gastric carcinoma [abstract]. Ann. Oncol. 191(13 Suppl.), 708P (2003).
29. Kim TW, Kang YK, Ahn JH et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol. 13(12), 1893-1898 (2002). This study was among the earliest to describe the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with AGC.
30. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008). Paper describing the Phase III REAL-2 study, which demonstrated that capecitabine could be substituted for 5-FU in triplet regimens for AGC.
31. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracilbased combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol. 20(9), 1529-1534 (2009). Meta-analysis demonstrating superiority of capecitabine versus 5-FU based on data from the REAL-2 and ML17032 noninferiority studies.
32. Chang C, Chao Y, Chen J et al. Pharmacoeconomic analysis of capecitabine for advanced gastric cancer in Taiwan. J. Clin. Oncol. 26, (2008) (Abstract 15576).
33. Boku N. Chemotherapy for metastatic disease: review from JCOG trials. Int. J. Clin. Oncol. 13(3), 196-200 (2008).
34. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol. 9(3), 215-221 (2008).
35. Ajani JA, Rodriquez W, Bodoky G et al. Multicenter Phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). Gastrointestinal Cancers Symposium (2009) (Abstract 8).
36. Lee JL, Kang YK, Kang HJ et al. A randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer 99(4), 584-590 (2008).
37. Lenz HJ, Lee FC, Haller DG et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter Phase II study. Cancer 109(1), 33-40 (2007).
38. Lee JL, Kang HJ, Kang YK et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother. Pharmacol. 61(5), 837-845 (2008).
39. Haller DG, Cassidy J, Clarke SJ et al. Potential regional differences for the tolerability profiles of fluoropyrimdines. J. Clin. Oncol. 26(13), 2118-2123 (2008).
40. Shirao K, Hoff PM, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: a joint United States and Japan Study of UFT/ LV. J. Clin. Oncol. 22(17), 3466-3474 (2004).
41. Al-Batran SE, Hartmann JT, Probst S et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26(9), 1435-1442 (2008).
42. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor recepter 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(18s), (2009) (Abstract LBA4509).
43. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357(18), 1810-1820 (2007).